Breast cancer brain metastases: the last frontier

Overview of attention for article published in Experimental Hematology & Oncology, November 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#5 of 298)
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

So far, Altmetric has seen 6 news stories from 6 outlets.

Primary and metastatic brain tumors present a significant therapeutic challenge, in large part because they are protected by…

Summary Onzeald (etirinotecan pegol) failed a trial in patients with metastatic breast cancer.

GlobeNewswire 2017-06-08 CAMBRIDGE, Mass., June 08, 2017 (GLOBE NEWSWIRE) -- 2X Oncology, Inc.

(GLOBE NEWSWIRE) -- 2X Oncology, Inc. ("2X" or the "Company"), a precision medicine company developing targeted therapeutics to…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 2 additional news stories.